<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20240731204941&amp;fc=20230708114047&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20240731204941&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 01 Aug 2024 00:49:42 +0000</lastbuilddate>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083704/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1461-1465. doi: 10.1161/CIRCULATIONAHA.124.069841. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083704/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39083704</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069841>10.1161/CIRCULATIONAHA.124.069841</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083704</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39083704</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069841</dc:identifier>
</item>
<item>
<title>Factors Underlying Reduced Hospitalizations for Myocardial Infarction During the COVID-19 Pandemic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083317/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The early reduction in AMI encounters was likely driven by care avoidance, while ongoing reductions through June 2023 likely reflect long-standing temporal trends. During the pandemic, there were 5% fewer AMI encounters than expected.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The incidence of hospital encounters for acute myocardial infarction (AMI) decreased sharply early in the COVID-19 pandemic and has not returned to prepandemic levels. There has been an ongoing debate about what mechanism may underlie this decline, including patients avoiding the hospital for treatment, excess mortality from COVID-19 among patients who would otherwise have had an AMI, a reduction in the incidence or severity of AMIs due to pandemic-related changes in behavior, or a preexisting temporal trend of lower AMI incidence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To describe drivers of changing incidence in AMI hospital encounters during the COVID-19 pandemic.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used traditional Medicare claims from all patients enrolled in traditional Medicare from January 2016 to June 2023 (total of 2.85 billion patient-months) to calculate the rate of AMI hospital encounters (emergency department visits, observation stays, or inpatient admissions) per capita at all short-term acute care and critical access hospitals in the United States overall and by patient characteristics. Observed rates were compared with expected rates that accounted for shifts in population characteristics and the prepandemic temporal trend (as estimated over 2016-2019). Data were analyzed in November 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Hospital encounters for AMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: On average, the study sample included 31 623 928 patients each month from January 2016 through June 2023, for a total of 2 846 153 487 patient-months during the 90-month study period. In June 2023, there were 0.044 AMI hospital encounters per 100 patients, which was 20% lower than in June 2019 (0.055 encounters per 100 patients). Early in the pandemic, AMI rates moved inversely with COVID-19 death rates and tracked patterns seen for other painful acute conditions, such as nephrolithiasis, suggesting these changes were associated with care avoidance. Changes in patient characteristics driven by excess deaths during the pandemic explained little of the decline. Later in the pandemic, the decline may be explained by the long-standing downward trend in AMI incidence; by April 2022, the observed rate of encounters matched the expected rate that accounted for this trend. During the full pandemic period, from March 2020 to June 2023, there were an estimated 5% (95% prediction interval, 1%-9%) fewer AMI hospital encounters than expected.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The early reduction in AMI encounters was likely driven by care avoidance, while ongoing reductions through June 2023 likely reflect long-standing temporal trends. During the pandemic, there were 5% fewer AMI encounters than expected.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083317/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39083317</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2031>10.1001/jamacardio.2024.2031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083317</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrew D Wilcock</dc:creator>
<dc:creator>Jose R Zubizarreta</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Kori S Zachrison</dc:creator>
<dc:creator>Lee H Schwamm</dc:creator>
<dc:creator>Ateev Mehrotra</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Factors Underlying Reduced Hospitalizations for Myocardial Infarction During the COVID-19 Pandemic</dc:title>
<dc:identifier>pmid:39083317</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2031</dc:identifier>
</item>
<item>
<title>Heart Failure-Together We Go Farther</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083307/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2181. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083307/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39083307</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2181>10.1001/jamacardio.2024.2181</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083307</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lorenz Van der Linden</dc:creator>
<dc:creator>Wilfried Mullens</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heart Failure-Together We Go Farther</dc:title>
<dc:identifier>pmid:39083307</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2181</dc:identifier>
</item>
<item>
<title>Leadless Ultrasound-Based Cardiac Resynchronization Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2067. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39083267</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2067>10.1001/jamacardio.2024.2067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083267</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Fred M Kusumoto</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Leadless Ultrasound-Based Cardiac Resynchronization Therapy</dc:title>
<dc:identifier>pmid:39083267</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2067</dc:identifier>
</item>
<item>
<title>Acute Myocardial Infarction Admissions During the COVID-19 Peak</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2187. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39083263</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2187>10.1001/jamacardio.2024.2187</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083263</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Vinay Guduguntla</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Acute Myocardial Infarction Admissions During the COVID-19 Peak</dc:title>
<dc:identifier>pmid:39083263</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2187</dc:identifier>
</item>
<item>
<title>Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083254/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The SOLVE-CRT study has demonstrated that leadless LV endocardial pacing with the WiSE CRT system is associated with a reduction in LVESV in patients with HF. This novel system may represent an alternative to conventional CRT implants in some HF patient populations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2050. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Approximately 40% of patients with heart failure (HF) who are eligible for cardiac resynchronization therapy (CRT) either fail to respond or are untreatable due to anatomical constraints.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the safety and efficacy of a novel, leadless, left ventricular (LV) endocardial pacing system for patients at high risk for a CRT upgrade or whose coronary sinus (CS) lead placement/pacing with a conventional CRT system failed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The SOLVE-CRT study was a prospective multicenter trial, enrolling January 2018 through September 2022, with follow-up in March 2023. Data were analyzed from DATE MONTH, YEAR, through DATE MONTH, YEAR. The trial combined data from an initial randomized, double-blind study (n = 108) and a subsequent single-arm part (n = 75). It took place at 36 centers across Australia, Europe, and the US. Participants were nonresponders, previously untreatable (PU), or high-risk upgrades (HRU). All participants contributed to the safety analysis. The primary efficacy analysis (n = 100) included 75 PU-HRU patients from the single-arm part and 25 PU-HRU patients from the randomized treatment arm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were implanted with the WiSE CRT System (EBR Systems) consisting of a leadless LV endocardial pacing electrode stimulated with ultrasound energy delivered by a subcutaneously implanted transmitter and battery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary safety end point was freedom from type I complications. The primary efficacy end point was a reduction in mean LV end systolic volume (LVESV).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 183 participants; mean age was 68.1 (SD, 10.3) years and 141 were male (77%). The trial was terminated at an interim analysis for meeting prespecified stopping criteria. In the safety population, patients were either New York Heart Association Class II (34.6%) or III (65.4%). The primary efficacy end point was met with a 16.4% (95% CI, -21.0% to -11.7%) reduction in mean LVESV (P = .003). The primary safety end point was met with an 80.9% rate of freedom from type I complications (P &lt; .001), which included 12 study device system events (6.6%), 5 vascular events (2.7%), 3 strokes (1.6%), and 7 cardiac perforations which mostly occurred early in the study (3.8%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The SOLVE-CRT study has demonstrated that leadless LV endocardial pacing with the WiSE CRT system is associated with a reduction in LVESV in patients with HF. This novel system may represent an alternative to conventional CRT implants in some HF patient populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT0292203.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083254/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39083254</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2050>10.1001/jamacardio.2024.2050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083254</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jagmeet P Singh</dc:creator>
<dc:creator>Christopher A Rinaldi</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Spencer H Kubo</dc:creator>
<dc:creator>Simon James</dc:creator>
<dc:creator>Imran K Niazi</dc:creator>
<dc:creator>Timothy Betts</dc:creator>
<dc:creator>Christian Butter</dc:creator>
<dc:creator>Toshimasa Okabe</dc:creator>
<dc:creator>Ryan Cunnane</dc:creator>
<dc:creator>Emad Aziz</dc:creator>
<dc:creator>Mauro Biffi</dc:creator>
<dc:creator>Amir Zaidi</dc:creator>
<dc:creator>Jeffrey Alison</dc:creator>
<dc:creator>Pascal Defaye</dc:creator>
<dc:creator>Angelo Aurrichio</dc:creator>
<dc:creator>Michael R Gold</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Tyson Rogers</dc:creator>
<dc:creator>Mary Norine Walsh</dc:creator>
<dc:creator>SOLVE-CRT Investigators</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure</dc:title>
<dc:identifier>pmid:39083254</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2050</dc:identifier>
</item>
<item>
<title>Change to Open Access Status</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2464. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39083251</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2464>10.1001/jamacardio.2024.2464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083251</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Change to Open Access Status</dc:title>
<dc:identifier>pmid:39083251</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2464</dc:identifier>
</item>
<item>
<title>Heart Failure-Together We Go Farther-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2184. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39083250</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2184>10.1001/jamacardio.2024.2184</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083250</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Amber B Tang</dc:creator>
<dc:creator>Nicholas K Brownell</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heart Failure-Together We Go Farther-Reply</dc:title>
<dc:identifier>pmid:39083250</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2184</dc:identifier>
</item>
<item>
<title>Haemodynamic changes after interventional closure of the left atrial appendage may facilitate peri-device leaks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39082746/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 31:ehae458. doi: 10.1093/eurheartj/ehae458. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39082746/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39082746</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae458>10.1093/eurheartj/ehae458</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39082746</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Claudia Stöllberger</dc:creator>
<dc:creator>Josef Finsterer</dc:creator>
<dc:creator>Birke Schneider</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Haemodynamic changes after interventional closure of the left atrial appendage may facilitate peri-device leaks</dc:title>
<dc:identifier>pmid:39082746</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae458</dc:identifier>
</item>
<item>
<title>Left atrial appendage occlusion leaks matter: the cryptic interplay of post-procedural haemodynamic changes and device surveillance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39082744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 31:ehae459. doi: 10.1093/eurheartj/ehae459. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39082744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39082744</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae459>10.1093/eurheartj/ehae459</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39082744</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Athanasios Samaras</dc:creator>
<dc:creator>Apostolos Tzikas</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left atrial appendage occlusion leaks matter: the cryptic interplay of post-procedural haemodynamic changes and device surveillance</dc:title>
<dc:identifier>pmid:39082744</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae459</dc:identifier>
</item>
<item>
<title>Single-nucleus RNA sequencing identifies cell-type-specific effects of sodium-glucose co-transporter 2 inhibitors in human myocardial slices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39082743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 31:ehae472. doi: 10.1093/eurheartj/ehae472. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39082743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39082743</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae472>10.1093/eurheartj/ehae472</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39082743</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Kevin Schmidt</dc:creator>
<dc:creator>Maximilian Fuchs</dc:creator>
<dc:creator>Natalie Weber</dc:creator>
<dc:creator>Christopher Werlein</dc:creator>
<dc:creator>Jan D Schmitto</dc:creator>
<dc:creator>Fabio Ius</dc:creator>
<dc:creator>Arjang Ruhparwar</dc:creator>
<dc:creator>Christian Bär</dc:creator>
<dc:creator>Jan Fiedler</dc:creator>
<dc:creator>Thomas Thum</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Single-nucleus RNA sequencing identifies cell-type-specific effects of sodium-glucose co-transporter 2 inhibitors in human myocardial slices</dc:title>
<dc:identifier>pmid:39082743</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae472</dc:identifier>
</item>
<item>
<title>Beyond the classic major cardiovascular event outcome for cardiovascular trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39082738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 31:ehae478. doi: 10.1093/eurheartj/ehae478. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39082738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39082738</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae478>10.1093/eurheartj/ehae478</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39082738</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mario Gaudino</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Beyond the classic major cardiovascular event outcome for cardiovascular trials</dc:title>
<dc:identifier>pmid:39082738</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae478</dc:identifier>
</item>
<item>
<title>Familial hypercholesterolaemia: need for equitable treatment in women and men</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39082699/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 31:ehae464. doi: 10.1093/eurheartj/ehae464. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39082699/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39082699</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae464>10.1093/eurheartj/ehae464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39082699</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Raul D Santos</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Familial hypercholesterolaemia: need for equitable treatment in women and men</dc:title>
<dc:identifier>pmid:39082699</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae464</dc:identifier>
</item>
<item>
<title>AMPK Attenuation of β-Adrenergic Receptor-Induced Cardiac Injury via Phosphorylation of β-Arrestin-1-ser330</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39082138/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AMPK phosphorylation of β-arrestin-1 Ser330 potentiated PDE4 expression and activity, thereby inhibiting β-AR/cAMP/PKA activation. Subsequently, β-arrestin-1 Ser330 phosphorylation blocks β-AR-induced cardiac inflammasome activation and remodeling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 31. doi: 10.1161/CIRCRESAHA.124.324762. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: β-adrenergic receptor (β-AR) overactivation is a major pathological cue associated with cardiac injury and diseases. AMPK (AMP-activated protein kinase), a conserved energy sensor, regulates energy metabolism and is cardioprotective. However, whether AMPK exerts cardioprotective effects via regulating the signaling pathway downstream of β-AR remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using immunoprecipitation, mass spectrometry, site-specific mutation, in vitro kinase assay, and in vivo animal studies, we determined whether AMPK phosphorylates β-arrestin-1 at serine (Ser) 330. Wild-type mice and mice with site-specific mutagenesis (S330A knock-in [KI]/S330D KI) were subcutaneously injected with the β-AR agonist isoproterenol (5 mg/kg) to evaluate the causality between β-adrenergic insult and β-arrestin-1 Ser330 phosphorylation. Cardiac transcriptomics was used to identify changes in gene expression from β-arrestin-1-S330A/S330D mutation and β-adrenergic insult.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Metformin could decrease cAMP/PKA (protein kinase A) signaling induced by isoproterenol. AMPK bound to β-arrestin-1 and phosphorylated Ser330 with the highest phosphorylated mass spectrometry score. AMPK activation promoted β-arrestin-1 Ser330 phosphorylation in vitro and in vivo. Neonatal mouse cardiomyocytes overexpressing β-arrestin-1-S330D (active form) inhibited the β-AR/cAMP/PKA axis by increasing PDE (phosphodiesterase) 4 expression and activity. Cardiac transcriptomics revealed that the differentially expressed genes between isoproterenol-treated S330A KI and S330D KI mice were mainly involved in immune processes and inflammatory response. β-arrestin-1 Ser330 phosphorylation inhibited isoproterenol-induced reactive oxygen species production and NLRP3 (NOD-like receptor protein 3) inflammasome activation in neonatal mouse cardiomyocytes. In S330D KI mice, the β-AR-activated cAMP/PKA pathways were attenuated, leading to repressed inflammasome activation, reduced expression of proinflammatory cytokines, and mitigated macrophage infiltration. Compared with S330A KI mice, S330D KI mice showed diminished cardiac fibrosis and improved cardiac function upon isoproterenol exposure. However, the cardiac protection exerted by AMPK was abolished in S330A KI mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AMPK phosphorylation of β-arrestin-1 Ser330 potentiated PDE4 expression and activity, thereby inhibiting β-AR/cAMP/PKA activation. Subsequently, β-arrestin-1 Ser330 phosphorylation blocks β-AR-induced cardiac inflammasome activation and remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39082138/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39082138</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324762>10.1161/CIRCRESAHA.124.324762</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39082138</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mingming Zhao</dc:creator>
<dc:creator>Ning Cao</dc:creator>
<dc:creator>Huijun Gu</dc:creator>
<dc:creator>Jiachao Xu</dc:creator>
<dc:creator>Wenli Xu</dc:creator>
<dc:creator>Di Zhang</dc:creator>
<dc:creator>Tong-You Wade Wei</dc:creator>
<dc:creator>Kang Wang</dc:creator>
<dc:creator>Ruiping Guo</dc:creator>
<dc:creator>Hongtu Cui</dc:creator>
<dc:creator>Xiaofeng Wang</dc:creator>
<dc:creator>Xin Guo</dc:creator>
<dc:creator>Zhiyuan Li</dc:creator>
<dc:creator>Kangmin He</dc:creator>
<dc:creator>Zijian Li</dc:creator>
<dc:creator>Youyi Zhang</dc:creator>
<dc:creator>John Y-J Shyy</dc:creator>
<dc:creator>Erdan Dong</dc:creator>
<dc:creator>Han Xiao</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>AMPK Attenuation of β-Adrenergic Receptor-Induced Cardiac Injury via Phosphorylation of β-Arrestin-1-ser330</dc:title>
<dc:identifier>pmid:39082138</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324762</dc:identifier>
</item>
<item>
<title>Prostacyclin Synthase Deficiency Leads to Exacerbation or Occurrence of Endothelium-Dependent Contraction and Causes Cardiovascular Disorders Mainly via the Non-TxA&lt;sub>;2&lt;/sub>; Prostanoids/TP Axis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39082135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study demonstrates that the non-TxA(2) prostanoids/TP axis plays an essential role in mediating the augmentation of EDC and cardiovascular disorders when PGIS is deficient, suggesting TP as a promising therapeutic target in diseases associated with PGIS insufficiency.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 31. doi: 10.1161/CIRCRESAHA.124.324924. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Prostaglandin I<sub>2</sub> synthesized by endothelial COX (cyclooxygenase) evokes potent vasodilation in some blood vessels but is paradoxically responsible for endothelium-dependent constriction (EDC) in others. Prostaglandin I<sub>2</sub> production and EDC may be enhanced in diseases such as hypertension. However, how PGIS (prostaglandin I<sub>2</sub> synthase) deficiency affects EDC and how this is implicated in the consequent cardiovascular pathologies remain largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Experiments were performed with wild-type, <i>Pgis</i> knockout (<i>Pgis</i><sup><i>-</i></sup><sup>/<i>-</i></sup>) and <i>Pgis</i>/thromboxane-prostanoid receptor gene (<i>Tp</i>) double knockout (<i>Pgis</i><sup><i>-</i>/<i>-</i></sup><i>Tp</i><sup><i>-</i>/<i>-</i></sup>) mice and <i>Pgis</i><sup><i>-</i>/<i>-</i></sup> mice transplanted with unfractionated wild-type or <i>Cox-1</i><sup><i>-</i>/<i>-</i></sup> bone marrow cells, as well as human umbilical arteries. COX-derived prostanoids were measured by high-performance liquid chromatography-mass spectrometry. Vasomotor responses of distinct types of arteries were assessed by isometric force measurement. Parameters of hypertension, vascular remodeling, and cardiac hypertrophy in mice at different ages were monitored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: PGF<sub>2α</sub>, PGE<sub>2</sub>, and a trace amount of PGD<sub>2</sub>, but not thromboxane A<sub>2</sub> (TxA<sub>2</sub>), were produced in response to acetylcholine in <i>Pgis</i><sup><i>-</i>/<i>-</i></sup> or PGIS-inhibited arteries. PGIS deficiency resulted in exacerbation or occurrence of EDC ex vivo and in vivo. Endothelium-dependent hyperpolarization was unchanged, but phosphorylation levels of eNOS (endothelial nitric oxide synthase) at Ser1177 and Thr495 were altered and NO production and the NO-dependent relaxation evoked by acetylcholine were remarkably reduced in <i>Pgis</i><sup><i>-</i>/<i>-</i></sup> aortas. <i>Pgis</i><sup><i>-</i>/<i>-</i></sup> mice developed high blood pressure and vascular remodeling at 16 to 17 weeks and subsequently cardiac hypertrophy at 24 to 26 weeks. Meanwhile, blood pressure and cardiac parameters remained normal at 8 to 10 weeks. Additional ablation of TP (TxA2 receptor) not only restrained EDC and the downregulation of NO signaling in <i>Pgis</i><sup><i>-</i>/<i>-</i></sup> mice but also ameliorated the cardiovascular abnormalities. Stimulation of <i>Pgis</i><sup><i>-</i>/<i>-</i></sup> vessels with acetylcholine in the presence of platelets led to increased TxA<sub>2</sub> generation. COX-1 disruption in bone marrow-derived cells failed to affect the development of high blood pressure and vascular remodeling in <i>Pgis</i><sup><i>-</i>/<i>-</i></sup> mice though it largely suppressed the increase of plasma TxB<sub>2</sub> (TxA<sub>2</sub> metabolite) level.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study demonstrates that the non-TxA<sub>2</sub> prostanoids/TP axis plays an essential role in mediating the augmentation of EDC and cardiovascular disorders when PGIS is deficient, suggesting TP as a promising therapeutic target in diseases associated with PGIS insufficiency.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39082135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39082135</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324924>10.1161/CIRCRESAHA.124.324924</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39082135</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiahui Ge</dc:creator>
<dc:creator>Yingbi Zhou</dc:creator>
<dc:creator>Hui Li</dc:creator>
<dc:creator>Ruhui Zeng</dc:creator>
<dc:creator>Kaiqi Xie</dc:creator>
<dc:creator>Jing Leng</dc:creator>
<dc:creator>Xijian Chen</dc:creator>
<dc:creator>Gang Yu</dc:creator>
<dc:creator>Xinya Shi</dc:creator>
<dc:creator>Yineng Xu</dc:creator>
<dc:creator>Dong He</dc:creator>
<dc:creator>Pi Guo</dc:creator>
<dc:creator>Yongyin Zhou</dc:creator>
<dc:creator>Hongjun Luo</dc:creator>
<dc:creator>Wenhong Luo</dc:creator>
<dc:creator>Bin Liu</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Prostacyclin Synthase Deficiency Leads to Exacerbation or Occurrence of Endothelium-Dependent Contraction and Causes Cardiovascular Disorders Mainly via the Non-TxA&lt;sub>;2&lt;/sub>; Prostanoids/TP Axis</dc:title>
<dc:identifier>pmid:39082135</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324924</dc:identifier>
</item>
<item>
<title>NaV1.5 autoantibodies in Brugada syndrome: pathogenetic implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39078224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The study demonstrates the presence of anti-NaV1.5 autoantibodies in the majority of BrS patients, suggesting an immunopathogenic component of the syndrome beyond genetic predispositions. These autoantibodies, which could serve as additional diagnostic markers, also prompt reconsideration of the underlying mechanisms of BrS, as evidenced by their role in inducing the ECG signature of the syndrome in wild-type mice. These findings encourage a more comprehensive diagnostic approach...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 30:ehae480. doi: 10.1093/eurheartj/ehae480. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients suffering from Brugada syndrome (BrS) are predisposed to life-threatening cardiac arrhythmias. Diagnosis is challenging due to the elusive electrocardiographic (ECG) signature that often requires unconventional ECG lead placement and drug challenges to be detected. Although NaV1.5 sodium channel dysfunction is a recognized pathophysiological mechanism in BrS, only 25% of patients have detectable SCN5A variants. Given the emerging role of autoimmunity in cardiac ion channel function, this study explores the presence and potential impact of anti-NaV1.5 autoantibodies in BrS patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using engineered HEK293A cells expressing recombinant NaV1.5 protein, plasma from 50 BrS patients and 50 controls was screened for anti-NaV1.5 autoantibodies via western blot, with specificity confirmed by immunoprecipitation and immunofluorescence. The impact of these autoantibodies on sodium current density and their pathophysiological effects were assessed in cellular models and through plasma injection in wild-type mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Anti-NaV1.5 autoantibodies were detected in 90% of BrS patients vs. 6% of controls, yielding a diagnostic area under the curve of .92, with 94% specificity and 90% sensitivity. These findings were consistent across varying patient demographics and independent of SCN5A mutation status. Electrophysiological studies demonstrated a significant reduction specifically in sodium current density. Notably, mice injected with BrS plasma showed Brugada-like ECG abnormalities, supporting the pathogenic role of these autoantibodies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The study demonstrates the presence of anti-NaV1.5 autoantibodies in the majority of BrS patients, suggesting an immunopathogenic component of the syndrome beyond genetic predispositions. These autoantibodies, which could serve as additional diagnostic markers, also prompt reconsideration of the underlying mechanisms of BrS, as evidenced by their role in inducing the ECG signature of the syndrome in wild-type mice. These findings encourage a more comprehensive diagnostic approach and point to new avenues for therapeutic research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39078224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39078224</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae480>10.1093/eurheartj/ehae480</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39078224</guid>
<pubDate>Tue, 30 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Adriana Tarantino</dc:creator>
<dc:creator>Giuseppe Ciconte</dc:creator>
<dc:creator>Dario Melgari</dc:creator>
<dc:creator>Anthony Frosio</dc:creator>
<dc:creator>Andrea Ghiroldi</dc:creator>
<dc:creator>Marco Piccoli</dc:creator>
<dc:creator>Marco Villa</dc:creator>
<dc:creator>Pasquale Creo</dc:creator>
<dc:creator>Serena Calamaio</dc:creator>
<dc:creator>Valerio Castoldi</dc:creator>
<dc:creator>Simona Coviello</dc:creator>
<dc:creator>Emanuele Micaglio</dc:creator>
<dc:creator>Federica Cirillo</dc:creator>
<dc:creator>Emanuela Teresina Locati</dc:creator>
<dc:creator>Gabriele Negro</dc:creator>
<dc:creator>Antonio Boccellino</dc:creator>
<dc:creator>Flavio Mastrocinque</dc:creator>
<dc:creator>Žarko Ćalović</dc:creator>
<dc:creator>Stefano Ricagno</dc:creator>
<dc:creator>Letizia Leocani</dc:creator>
<dc:creator>Gabriele Vicedomini</dc:creator>
<dc:creator>Vincenzo Santinelli</dc:creator>
<dc:creator>Ilaria Rivolta</dc:creator>
<dc:creator>Luigi Anastasia</dc:creator>
<dc:creator>Carlo Pappone</dc:creator>
<dc:date>2024-07-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>NaV1.5 autoantibodies in Brugada syndrome: pathogenetic implications</dc:title>
<dc:identifier>pmid:39078224</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae480</dc:identifier>
</item>
<item>
<title>Prophylactic perigraft to right atrial shunt controls bleeding from the right coronary ostial anastomotic leak</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39078206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 30:ehae487. doi: 10.1093/eurheartj/ehae487. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39078206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39078206</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae487>10.1093/eurheartj/ehae487</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39078206</guid>
<pubDate>Tue, 30 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Zihao Li</dc:creator>
<dc:creator>Hongwei Zhang</dc:creator>
<dc:creator>Zhao Li</dc:creator>
<dc:date>2024-07-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prophylactic perigraft to right atrial shunt controls bleeding from the right coronary ostial anastomotic leak</dc:title>
<dc:identifier>pmid:39078206</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae487</dc:identifier>
</item>
<item>
<title>Potential new therapeutic target for HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39075216/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 29. doi: 10.1038/s41569-024-01066-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39075216/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39075216</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01066-2>10.1038/s41569-024-01066-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39075216</guid>
<pubDate>Mon, 29 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-07-29</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Potential new therapeutic target for HFpEF</dc:title>
<dc:identifier>pmid:39075216</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01066-2</dc:identifier>
</item>
<item>
<title>Correction to: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39074185/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 30;150(5):e105. doi: 10.1161/CIR.0000000000001272. Epub 2024 Jul 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39074185/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39074185</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001272>10.1161/CIR.0000000000001272</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39074185</guid>
<pubDate>Mon, 29 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39074185</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001272</dc:identifier>
</item>
<item>
<title>IGFBP7: From Senescence Biomarker to a Vaccine for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39074184/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 30;150(5):390-392. doi: 10.1161/CIRCULATIONAHA.124.067059. Epub 2024 Jul 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39074184/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39074184</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067059>10.1161/CIRCULATIONAHA.124.067059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39074184</guid>
<pubDate>Mon, 29 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Joseph Pierre Aboumsallem</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:date>2024-07-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>IGFBP7: From Senescence Biomarker to a Vaccine for Heart Failure</dc:title>
<dc:identifier>pmid:39074184</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.067059</dc:identifier>
</item>
<item>
<title>Response by Lambiase and van Duijvenboden to Letter Regarding Article, "Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39074183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240731204941&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 30;150(5):e104. doi: 10.1161/CIRCULATIONAHA.124.069705. Epub 2024 Jul 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39074183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240731204941&v=2.18.0.post9+e462414">39074183</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069705>10.1161/CIRCULATIONAHA.124.069705</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39074183</guid>
<pubDate>Mon, 29 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Stefan van Duijvenboden</dc:creator>
<dc:date>2024-07-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Lambiase and van Duijvenboden to Letter Regarding Article, "Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects"</dc:title>
<dc:identifier>pmid:39074183</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069705</dc:identifier>
</item>





























</channel>
</rss>